Bayer HealthCare Pharmaceuticals is the pharmaceutical division of Bayer HealthCare AG. It markets products in more than 100 countries and in 2011 the company generated sales of almost € 10 billion. More than 37,000 members of staff currently work for Bayer HealthCare Pharmaceuticals worldwide – more than 6,500 in research and development alone.
Operations are concentrated on five big therapeutic groups:
Cardiovascular and blood diseases
Oncological diseases
Ophthalmology
Women's healthcare
Imaging techniques
We aim to improve people’s quality of life with our products. To achieve this, we concentrate on the research and development of innovative drugs and novel therapeutic approaches. At the same time, we are constantly improving established products. In this context, Bayer HealthCare Pharmaceuticals uses experience it has gained from over a century in the business.
Therapeutic Areas
Age-related macular degeneration (AMD)
Breast cancer
Central retinal vein occlusion (CRVO)
Colorectal Cancer (CRC)
Contraception
Diabetes
Diabetic macular edema (DME)
Endometriosis
Erectile dysfunction
Gastrointestinal stromal tumor (GIST)
Gynecological therapy
Heart attack
Heart attack and stroke
Hemophilia
High blood pressure
Infectious diseases
Liver cancer
Menopausal complaints
Multiple sclerosis
Peripheral arterial occlusive disease
Premenstrual dysphoric disorder (PMDD)
Prostate cancer
Pulmonary arterial hypertension
Renal cell carcinoma
Stroke
Testosterone deficiency
Thrombosis
Thyroid cancer
Research Areas
In its internal research for active ingredients, Bayer HealthCare Pharmaceuticals concentrates on four core areas: Oncology, Cardiology, Women´s Healthcare, and Diagnostic Imaging. With new approaches in cancer therapy, cardiovascular diseases, gynecological therapies, and molecular imaging, we aim to become the innovation leader in these areas.
